# Fortis Healthcare share price today (Fortis Healthcare Ltd, NSE: FORTIS)

> Fortis Healthcare share price today: ₹785.55 at the NSE close on 3 November 2026, down 23.2% in a year. Fortis Healthcare (NSE: FORTIS) is worth ₹59,317 crore, trades at a P/E of 55.6 and has closed between ₹712.90 and ₹1,020.00 over the past 52 weeks. > Fortis Healthcare Ltd's earnings have grown faster than its share price. Earnings per share grew +34.5% in a year while the price moved −23.2%. FORTIS · Hospitals · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/fortis-healthcare-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from fewer quarters than usual
- Price: ₹785.55 (−23.2% in a year)
- P/E: 55.6× (lower than 61% of the last 11 years)
- Revenue (Jun 2026): ₹2,545 Cr (+17.4% on a year ago)
- Profit (Jun 2026): ₹273 Cr (+2.2% on a year ago)
- Operating margin: 21.0% (−2.0 points on a year ago)
- ROCE: 13%, FY26
- Profit that came in as cash: 164%, last 3 years

The main question: yearly earnings per share moved +34.5% while the share price moved −23.2%. ## What is the Fortis Healthcare share price today? Fortis Healthcare Ltd's share price was ₹785.55 at the close on 3 November 2026. It has been falling for 4 weeks. That is 10.6% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹713 and ₹1,020, and at that close it sat 24% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 20 weeks running. Over the last 11 years the share price moved +359% while the NIFTY 500 moved +249%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 25 June 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Fortis Healthcare this quarter? Three changes stood out: revenue up on a year earlier for 11 quarters in a row (every quarter we can compare), indian funds and insurers (DIIs) raised their stake for 4 quarters in a row and foreign funds (FIIs) cut their stake for 4 quarters in a row. 1. Revenue up on a year earlier for 11 quarters in a row (every quarter we can compare) In the June 2026 quarter revenue was ₹2,545 crore, +17.4% on a year earlier. 2. Indian funds and insurers (DIIs) raised their stake for 4 quarters in a row From 29.1% to 34.5% of the company by the September 2026 quarter. 3. Foreign funds (FIIs) cut their stake for 4 quarters in a row From 27.9% to 23.2% of the company by the September 2026 quarter. ## What are Fortis Healthcare's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Fortis Healthcare reported revenue of ₹2,545 crore, up 17.4% from ₹2,167 crore a year earlier, and a profit of ₹273 crore, up 2.2% from ₹267 crore. ### Fortis Healthcare results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹2,545 crore | ₹2,167 crore | +17.4% |
| Profit | ₹273 crore | ₹267 crore | +2.2% |
| Earnings per share | ₹3.53 | ₹3.45 | +2.3% |
| Operating margin | 21.0% | 23.0% | −2.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Fortis Healthcare's management discussed these results on a call held on 4 September 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Fortis Healthcare share price history? Fortis Healthcare closed at ₹785.55 on 3 November 2026, down 23.2% from ₹1,023.05 a year earlier (31 October 2025) and up 211.3% over five years. Its highest weekly close since March 2016 was ₹1,084.90 on 17 October 2025. ### Fortis Healthcare share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹712.90 | +10.2% |
| 1 month ago · 1 Oct 2026 | ₹785.00 | +0.1% |
| 6 months ago · 30 Apr 2026 | ₹922.95 | −14.9% |
| 1 year ago · 31 Oct 2025 | ₹1,023.05 | −23.2% |
| 3 years ago · 3 Nov 2023 | ₹334.10 | +135.1% |
| 5 years ago · 4 Nov 2021 | ₹252.35 | +211.3% |
| 10 years ago · 4 Nov 2016 | ₹168.70 | +365.6% |
| Earliest weekly close in our records · 4 Mar 2016 | ₹171.05 | +359.3% |
| Highest weekly close since March 2016 · 17 Oct 2025 | ₹1,084.90 | −27.6% |
| Lowest weekly close since March 2016 · 22 May 2020 | ₹114.15 | +588.2% |
| 52-week high (weekly close) · 7 Nov 2025 | ₹1,020.00 | −23.0% |
| 52-week low (weekly close) · 23 Oct 2026 | ₹712.90 | +10.2% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (564 weekly closes from 4 March 2016 to 3 November 2026.)

## What is the latest news on Fortis Healthcare? 3 Nov 2026: Fortis Healthcare closed at ₹785.55, up 10.2% on the week and up 0.1% on the month. 4 Sep 2026: Fortis Healthcare held its results call for April to June 2026. Management guided: IHH to keep backing Fortis, provide capital if needed within legal limits and consider a Gleneagles-Fortis merger at the appropriate time; internal accruals to drive most growth. ### Earlier

- 24 Jul 2026: ex-date for a dividend of ₹1 a share. - Results for April to June 2026: Revenue up 17.4% and profit up 2.2% on a year earlier. ## What dividend does Fortis Healthcare pay? Fortis Healthcare paid ₹1 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.13% at the ₹785.55 close on 3 November 2026. The last was a dividend of ₹1 a share, ex-date 24 July 2026. ### Fortis Healthcare dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 24 Jul 2026 | ₹1 | Dividend |
| 25 Jul 2025 | ₹1 | Dividend |
| 24 Jul 2024 | ₹1 | Dividend |
| 20 Jul 2023 | ₹1 | Dividend |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 3 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Fortis Healthcare Ltd paid out 7% of its profit as dividends in FY26, and it paid a dividend in 4 of its last 13 reported years. One of those years shows a negative figure because profit itself was negative. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Fortis Healthcare management say on the latest results call? On the call for April to June 2026, held on 4 September 2026, Fortis Healthcare's management guided: IHH to keep backing Fortis, provide capital if needed within legal limits and consider a Gleneagles-Fortis merger at the appropriate time; internal accruals to drive most growth. > “However, I am not sure why they are wrongly accusing us of wrongdoing when we are neither the judgment debtors nor were we garnishees at any stage. It is unfair to us, so we will definitely consider whatever actions we can take to protect the interests of our company.”
> Dr. Ashutosh Raghuvanshi, MD & CEO, on the call for April to June 2026

### What management guided

- IHH commitment to raise its Fortis stake to 50% and above continues; timeframe not restated on this call. - Fortis will cooperate if the audit proceeds; counsel to determine challenge or other steps over the next 5-10 days. - Court-directed audit process: questionnaire in 4 weeks, responses in 2 weeks and report in 6 months; post-report actions may take a few months. - Ongoing legal expenditure to continue; current-year level difficult to predict and dependent on case intensity. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/4728/Conference Call/CC-Sep26.pdf). (From the call for April to June 2026, 4 September 2026.)

## What to watch in Fortis Healthcare's next results? When Fortis Healthcare reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Court-directed audit to reach each stated procedural milestone, including information requests, responses and the final report. - What to check (from the call)
- Court-directed audit to reach each stated procedural milestone, including information requests, responses and the final report. - Counsel's decision on any challenge or appropriate-forum action to emerge after reviewing the order. - Any new liability, provision or adverse finding beyond the currently stated balance-sheet position. - Employee, doctor or patient disruption, or M&A slowdown, despite management's stated operational insulation. ## Which stock lists is Fortis Healthcare on? Fortis Healthcare is on one of our India lists: Small & mid cap stocks. [Small & mid cap stocks Size rank in India: 171](https://www.sectoralpha.in/small-cap-stocks-india)

## Is Fortis Healthcare profitable? Fortis Healthcare Ltd earned ₹273 Cr of net profit in the Jun 2026 quarter, +2.2% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹1,064 Cr. Over 10 years profit has grown 38.2% a year on average. That is 10.7% of the quarter's revenue. The same quarter a year earlier earned ₹267 Cr. For the full year, FY26 profit was ₹1,064 Cr (+31.5% on the year before). Why profit moved: revenue changed +17.4% on a year earlier and the margin moved −2.0 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed +23.6% and revenue +17.5%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Fortis Healthcare make, and is it growing? Fortis Healthcare Ltd reported ₹2,545 Cr of revenue in the Jun 2026 quarter, +17.4% on the same quarter a year earlier. That is the 11th quarter in a row with growth on the year before. Over 10 years it has grown 8.1% a year on average. The last full year, FY26, came in at ₹9,128 Cr. The last four reported quarters add to ₹9,506 Cr. FY26 revenue was ₹9,128 Cr, +17.3% on the year before. Recent pace: the last four quarters grew +17.5% on average, against 8.1% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +17.5%, against +15.8% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +18.6%, against +24.1% a year (rolling over). ## How much of every ₹100 of sales does Fortis Healthcare keep? Fortis Healthcare Ltd's operating margin was 21.0% in the Jun 2026 quarter, 2.0 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between 2.0% and 23.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −1.5 percentage points on the year while gross margin changed +1.2 points. So the drop came mostly from the gross margin, which means input costs and prices charged. As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead. ## Is Fortis Healthcare's profit turning into cash? Over the last 3 years, 164% of Fortis Healthcare Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹1,601 Cr of operating cash against ₹1,064 Cr of profit. After ₹2,282 Cr of spending on assets, free cash was −₹681 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 164% of profit came in as cash: the cash cycle got 36 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 3.6× depreciation over three years. The next section checks what that spending is building. ## Where does Fortis Healthcare's cash go? Fortis Healthcare Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was −99 days in FY26, up from −135 days in FY21. It spent ₹4,187 Cr on assets over the last 3 years. Customers take 42 days to pay, and stock sits for 24 days on average. At FY26 sales of ₹9,128 Cr, each day of that cycle ties up about ₹25.0 Cr, so roughly −₹2,476 Cr is tied up in the business at any time. FY26: customers took 42 days to pay and stock sat for 24 days, about 0.8 months of sales sitting as stock, for a full cycle of −99 days, longer than FY21's −135. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 24 days. Customers pay about 42 days after that. Suppliers are paid at 165 days. Together that makes the −99-day cycle. Spending on assets: ₹4,187 Cr over the last 3 years, against ₹1,177 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹434 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Fortis Healthcare's P/E ratio, and how does it compare with its own history? Fortis Healthcare Ltd's P/E is 55.6×, in the middle of its own history: higher than 39% of past readings. Its usual P/E (the middle reading) is 61.7×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹13.88. Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks. Why the multiple is where it is: over the past year earnings per share moved +34.5% while the price moved −23.2%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved +25.5% a year; about +45.0% a year came from earnings growth and about −19.5 percentage points from the multiple (the market paying less); over 10 years the price moved +16.6% a year; about +30.4% a year came from earnings growth and about −13.8 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. The PEG ratio and its quarterly curve, which only the second data source has, are not shown on this page: its two data sources disagree by up to 12% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Is the Fortis Healthcare business getting better or worse? Fortis Healthcare Ltd's business is giving mixed signals. There is no clear direction across the growth lines, with ROCE rising at 13.0%; each line tells part of the story. This is based on 8 quarters of 4 measures, with some gaps. Why it matters: when the lines disagree, each line above matters more than any single label. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## How much does Fortis Healthcare earn on its capital? Fortis Healthcare Ltd earned a ROCE of 13% in FY26. That is up from a low of 0% in FY14. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 11.7% net margin and 0.58× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 11.7% net margin × 0.58× asset turnover × 1.60× leverage (assets divided by equity) ≈ 10.9% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 12% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Does Fortis Healthcare have too much debt? Fortis Healthcare Ltd had ₹3,473 Cr of borrowings against ₹9,896 Cr of equity in FY26, so its debt is 0.35× its equity. Its operating profit is 7 times its interest bill. Over 5 years borrowings went from ₹1,531 Cr to ₹3,473 Cr. Over the last 3 of those years it spent ₹4,187 Cr on assets. Part of the spending on assets is being paid for with borrowed money. The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 12% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What is the Fortis Healthcare shareholding pattern? Domestic institutions raised their stake in Fortis Healthcare Ltd by 3.7 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 34.5% of the company. Foreign institutions moved −2.1 points over the same period, to 23.2%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: +3.7 points over 8 quarters, to 34.5%; Foreign institutions: −2.1 points over 8 quarters, to 23.2%; Promoters: +0.0 points over 8 quarters, to 31.2%. Why the owners changed: foreign institutions moved −2.1 points and domestic institutions +3.7 points over 8 quarters, while promoters stayed about the same. One group of institutions took over shares from the other; it is not a change of mind by the people running the company. ## How far is Fortis Healthcare from balance-sheet trouble? For Fortis Healthcare Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Fortis Healthcare rank in its industry? 45.1 out of 100, rank 13 of 20 in Hospitals, with 78% of the evidence available. Fortis Healthcare Ltd scores 45.1 out of 100 against the 20 companies it is compared with in Hospitals, ranking 13. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 19.8 + 12.7 + 10.6 + 2 = 45.1. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Fortis Healthcare compared with? Fortis Healthcare ranks 13 of 20 Hospitals companies on the 4-Factor Sector Score, with 45.1 out of 100. 1. [KMC Speciality Hospitals (India) Ltd](https://www.sectoralpha.in/stocks/kmc-speciality-hospitals-indialtd) KMCSHIL · breaking out · Sector-leading setup · 81% evidence 80.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.0/35 · Revenue 35.1% · Profit 100% · Operating margin change 6 points · 88% evidence Capital efficiency 23.1/25 · ROCE 26.2% · Operating margin 31% · 100% evidence Valuation 14.1/20 · P/E 43.4× · PEG 0.68 · 100% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 45.6% · 1 year 115.4% · 25% evidence · 5 of 5 weeks ahead Exact sum: 31 + 23.1 + 14.1 + 12.5 = 80.7 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Sakar Healthcare Ltd](https://www.sectoralpha.in/stocks/sakar-healthcare-ltd) SAKAR · leader · Most evidence points up · 100% evidence 68.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.5/35 · Revenue 47.5% · Profit 100% · Operating margin change 8 points · 100% evidence Capital efficiency 11.5/25 · ROCE 12.4% · Operating margin 28% · 100% evidence Valuation 11.1/20 · P/E 49× · PEG 1.05 · 100% evidence Relative strength 13.8/20 · Lead over its industry 41.8% · Lead over NIFTY 500 45.4% · 1 year 161.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 32.5 + 11.5 + 11.1 + 13.8 = 68.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Apollo Hospitals Enterprise Ltd](https://www.sectoralpha.in/stocks/apollo-hospitals-enterprise-ltd) APOLLOHOSP · turning · Most evidence points up · 78% evidence 68.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 17.2% · Profit 33.2% · Operating margin change 1 points · 83% evidence Capital efficiency 15.2/25 · ROCE 17.4% · Operating margin 16% · 76% evidence Valuation 12.7/20 · P/E 57.7× · PEG n/a · 50% evidence Relative strength 16.6/20 · Lead over its industry 6.6% · Lead over NIFTY 500 11.2% · 1 year 10% · 100% evidence · 4 of 12 weeks ahead Exact sum: 24 + 15.2 + 12.7 + 16.6 = 68.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Dr Agarwals Eye Hospital Ltd](https://www.sectoralpha.in/stocks/dr-agarwals-eye-hospital-ltd) DRAGARWQ · breaking out · Evidence leans up · 81% evidence 62.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.1/35 · Revenue 20.1% · Profit 31.6% · Operating margin change -2 points · 88% evidence Capital efficiency 17.4/25 · ROCE 17.2% · Operating margin 30% · 100% evidence Valuation 12.5/20 · P/E 33.7× · PEG 1.36 · 100% evidence Relative strength 11.6/20 · Lead over its industry n/a · Lead over NIFTY 500 9.2% · 1 year 0.8% · 25% evidence · 8 of 12 weeks ahead Exact sum: 21.1 + 17.4 + 12.5 + 11.6 = 62.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Kovai Medical Center & Hospital Ltd](https://www.sectoralpha.in/stocks/kovai-medical-center-hospital-ltd) KOVAI · breaking out · Evidence leans up · 96% evidence 61.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.8/35 · Revenue 15% · Profit 15.8% · Operating margin change 1 points · 88% evidence Capital efficiency 19.1/25 · ROCE 22.6% · Operating margin 29% · 100% evidence Valuation 8.9/20 · P/E 24.8× · PEG 2.01 · 100% evidence Relative strength 14.7/20 · Lead over its industry 1.9% · Lead over NIFTY 500 6.6% · 1 year -9.2% · 100% evidence · 10 of 12 weeks ahead Exact sum: 18.8 + 19.1 + 8.9 + 14.7 = 61.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [GPT Healthcare Ltd](https://www.sectoralpha.in/stocks/gpt-healthcare-ltd) GPTHEALTH · quiet · Evidence leans up · 81% evidence 61.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.4/35 · Revenue 18% · Profit 0% · Operating margin change 3 points · 88% evidence Capital efficiency 18.2/25 · ROCE 19.9% · Operating margin 19% · 100% evidence Valuation 18.5/20 · P/E 23× · PEG 0.94 · 100% evidence Relative strength 9.1/20 · Lead over its industry n/a · Lead over NIFTY 500 -2.1% · 1 year -10.7% · 25% evidence · 4 of 12 weeks ahead Exact sum: 15.4 + 18.2 + 18.5 + 9.1 = 61.2 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 7. [Yatharth Hospital & Trauma Care Services Ltd](https://www.sectoralpha.in/stocks/yatharth-hospital-trauma-care-services-ltd) YATHARTH · breaking out · Evidence leans up · 78% evidence 57.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.4/35 · Revenue 43.9% · Profit 22.5% · Operating margin change -2 points · 83% evidence Capital efficiency 12.4/25 · ROCE 12.9% · Operating margin 23% · 76% evidence Valuation 6.7/20 · P/E 49.3× · PEG n/a · 50% evidence Relative strength 19.1/20 · Lead over its industry 17.1% · Lead over NIFTY 500 21.6% · 1 year 16.4% · 100% evidence · 10 of 12 weeks ahead Exact sum: 19.4 + 12.4 + 6.7 + 19.1 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Artemis Medicare Services Ltd](https://www.sectoralpha.in/stocks/artemis-medicare-services-ltd) ARTEMISMED · leader · Evidence leans up · 100% evidence 56.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.4/35 · Revenue 14.7% · Profit 20% · Operating margin change 0 points · 100% evidence Capital efficiency 12.8/25 · ROCE 14.6% · Operating margin 18% · 100% evidence Valuation 8.0/20 · P/E 39.7× · PEG 2.44 · 100% evidence Relative strength 16.7/20 · Lead over its industry 8.4% · Lead over NIFTY 500 12.9% · 1 year 18.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 19.4 + 12.8 + 8 + 16.7 = 56.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Indraprastha Medical Corporation Ltd](https://www.sectoralpha.in/stocks/indraprastha-medical-corporation-ltd) INDRAMEDCO · quiet · Evidence leans up · 85% evidence 51.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.3/35 · Revenue 10.8% · Profit 10.9% · Operating margin change 0 points · 100% evidence Capital efficiency 17.6/25 · ROCE 35.8% · Operating margin 19% · 100% evidence Valuation 13.2/20 · P/E 14.6× · PEG 1.47 · 100% evidence Relative strength 7.7/20 · Lead over its industry n/a · Lead over NIFTY 500 -19.7% · 1 year -49.6% · 25% evidence · 0 of 12 weeks ahead Exact sum: 13.3 + 17.6 + 13.2 + 7.7 = 51.8 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 10. [Global Health Ltd](https://www.sectoralpha.in/stocks/global-health-ltd) MEDANTA · losing its lead · Evidence leans up · 96% evidence 50.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.5/35 · Revenue 21.3% · Profit 3.4% · Operating margin change -2 points · 88% evidence Capital efficiency 17.3/25 · ROCE 17.4% · Operating margin 22% · 100% evidence Valuation 5.5/20 · P/E 59.7× · PEG 9.11 · 100% evidence Relative strength 14.2/20 · Lead over its industry 3.7% · Lead over NIFTY 500 8.1% · 1 year -3.1% · 100% evidence · 8 of 12 weeks ahead Exact sum: 13.5 + 17.3 + 5.5 + 14.2 = 50.5 · What this means: Relative strength against the index is 8.1%, and revenue and profit growth are weak. 11. [Rainbow Childrens Medicare Ltd](https://www.sectoralpha.in/stocks/rainbow-childrens-medicare-ltd) RAINBOW · quiet · Evidence leans up · 100% evidence 50.3 out of 100 Growth Capital Valuation Relative
12. [Max Healthcare Institute Ltd](https://www.sectoralpha.in/stocks/max-healthcare-institute-ltd) MAXHEALTH · quiet · Evidence leans down · 85% evidence 48.7 out of 100 Growth Capital Valuation Relative
13. Fortis Healthcare Ltd this page FORTIS · basing · Evidence leans down · 78% evidence 45.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.8/35 · Revenue 17.5% · Profit 18.6% · Operating margin change -2 points · 83% evidence Capital efficiency 12.7/25 · ROCE 13.4% · Operating margin 21% · 76% evidence Valuation 10.6/20 · P/E 54.4× · PEG n/a · 50% evidence Relative strength 2.0/20 · Lead over its industry -14.2% · Lead over NIFTY 500 -10.1% · 1 year -24.9% · 100% evidence · 0 of 12 weeks ahead Exact sum: 19.8 + 12.7 + 10.6 + 2 = 45.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 14. [Shalby Ltd](https://www.sectoralpha.in/stocks/shalby-ltd) SHALBY · quiet · Evidence leans down · 63% evidence 42.0 out of 100 Growth Capital Valuation Relative
15. [Narayana Hrudayalaya Ltd](https://www.sectoralpha.in/stocks/narayana-hrudayalaya-ltd) NH · quiet · Evidence leans down · 78% evidence 40.8 out of 100 Growth Capital Valuation Relative
16. [Aster DM Quality Care Ltd](https://www.sectoralpha.in/stocks/aster-dm-quality-care-ltd) ASTERDM · quiet · Evidence leans down · 96% evidence 35.2 out of 100 Growth Capital Valuation Relative
17. [Krishna Institute of Medical Sciences Ltd](https://www.sectoralpha.in/stocks/krishna-institute-of-medical-sciences-ltd) KIMS · quiet · Most evidence points down · 78% evidence 34.8 out of 100 Growth Capital Valuation Relative
18. [Jupiter Life Line Hospitals Ltd](https://www.sectoralpha.in/stocks/jupiter-life-line-hospitals-ltd) JLHL · quiet · Most evidence points down · 100% evidence 33.0 out of 100 Growth Capital Valuation Relative
19. [Healthcare Global Enterprises Ltd](https://www.sectoralpha.in/stocks/healthcare-global-enterprises-ltd) HCG · quiet · Most evidence points down · 71% evidence 31.1 out of 100 Growth Capital Valuation Relative
20. [Manipal Health Enterprises Ltd](https://www.sectoralpha.in/stocks/manipal-health-enterprises-ltd) MANIPALHOS · Too little evidence to rank firmly · 38% evidence 42.4 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Hospitals](https://www.sectoralpha.in/sectors/hospitals), all 20 compared on one page. ## Which companies are close to Fortis Healthcare in size? Fortis Healthcare is the 5th largest of 20 Hospitals companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Manipal Health Enterprises, Max Healthcare Institute and Aster DM Quality Care. Just below it: Narayana Hrudayalaya, Global Health and Krishna Institute of Medical Sciences. ### Hospitals companies close in size

1. [Manipal Health Enterprises Ltd](https://www.sectoralpha.in/stocks/manipal-health-enterprises-ltd) ₹88,018 crore
2. [Max Healthcare Institute Ltd](https://www.sectoralpha.in/stocks/max-healthcare-institute-ltd) ₹83,705 crore
3. [Aster DM Quality Care Ltd](https://www.sectoralpha.in/stocks/aster-dm-quality-care-ltd) ₹59,374 crore
4. Fortis Healthcare Ltd ₹57,992 crore
5. [Narayana Hrudayalaya Ltd](https://www.sectoralpha.in/stocks/narayana-hrudayalaya-ltd) ₹35,154 crore
6. [Global Health Ltd](https://www.sectoralpha.in/stocks/global-health-ltd) ₹34,156 crore
7. [Krishna Institute of Medical Sciences Ltd](https://www.sectoralpha.in/stocks/krishna-institute-of-medical-sciences-ltd) ₹29,476 crore

[All 20 Hospitals companies, largest first](https://www.sectoralpha.in/sectors/hospitals#all-companies)

### Companies close in size in other industries

1. [Torrent Power Ltd](https://www.sectoralpha.in/stocks/torrent-power-ltd) ₹59,103 crore · Power - Generation/Distribution
2. [Adani Total Gas Ltd](https://www.sectoralpha.in/stocks/adani-total-gas-ltd) ₹58,779 crore · Gas Distribution
3. Fortis Healthcare Ltd ₹57,992 crore
4. [Indo-MIM Ltd](https://www.sectoralpha.in/stocks/indo-mim-ltd) ₹57,933 crore · Engineering - Light - General
5. [Nippon Life India Asset Management Ltd](https://www.sectoralpha.in/stocks/nippon-life-india-asset-management-ltd) ₹57,924 crore · Finance - AMC

## What else do people ask about Fortis Healthcare? ### What is Fortis Healthcare's share price today? Fortis Healthcare Ltd's share price is ₹785.55, −23.2% over the past year. The whole company is worth ₹59,317 Cr on the market. In the last 52 weeks it traded between ₹713 to ₹1,020; today it is 24% of the way up from the low, 10.6% below its 200-day average (as of 3 November 2026). ### What were Fortis Healthcare's latest quarterly results? Fortis Healthcare Ltd reported revenue of ₹2,545 Cr and net profit of ₹273 Cr for the Jun 2026 quarter. Revenue rose 17.4% and profit rose 2.2% compared with a year earlier. Earnings per share were ₹3.53. The operating margin was 21.0%, 2.0 percentage points lower than a year earlier (as of 3 November 2026). ### What is Fortis Healthcare's market cap? Fortis Healthcare Ltd's market capitalisation is ₹59,317 Cr at a share price of ₹785.55. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Fortis Healthcare performing? Fortis Healthcare Ltd's share price has been falling for 4 weeks. In its latest quarter, revenue rose 17.4% and profit rose 2.2% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 20 weeks running (as of 3 November 2026). ### Will Fortis Healthcare's share price go up? This page does not forecast Fortis Healthcare Ltd's share price. What it shows instead: the share price is ₹785.55, and it has been falling for 4 weeks. Its P/E of 55.6× is higher than 39% of its own last 11 years (as of 3 November 2026). ### Where is Fortis Healthcare in its business cycle? Fortis Healthcare Ltd's FY26 operating margin was 23.0%, against a 13-year range of 2.0% to 23.0%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 21.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Fortis Healthcare story? The main question: yearly earnings per share moved +34.5% while the share price moved −23.2%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Fortis Healthcare a stock worth studying right now? What the numbers show: Fortis Healthcare Ltd's earnings have grown faster than its share price. Earnings per share grew +34.5% in a year while the price moved −23.2%. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Fortis Healthcare share price forecast for 2026? What management itself guided: IHH to keep backing Fortis, provide capital if needed within legal limits and consider a Gleneagles-Fortis merger at the appropriate time; internal accruals to drive most growth. ## Lists

- Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india

This is research, not advice. We’re not SEBI-registered.